Submitted:
21 September 2023
Posted:
25 September 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Clinical Case
3. Discussion
3.1. Pathophysiology
3.2. Diagnostic
3.3. Treatment
4. Conclusion
Abbreviations
References
- P.M. Mortimer, S.A. Mc Intyre, D.C. Thomas. Beyond the extra respiration of phagocytosis: NADPH oxidase 2 in adaptive immunity and inflammation. Front. Immunol., 12 (2021), . [CrossRef]
- D.C. Thomas, S. Clare, J.M. Sowerby, M. Pardo, J.K. Juss, D.A.Goulding, et al. Eros is a novel transmembrane protein that controls the phagocyte respiratory burst and is essential for innate immunity. J. Exp. Med., 214 (2017), pp. 1111-1128.
- D.C. Thomas, L.-M. Charbonnier, A. Schejtman, H. Aldhekri, E.L.Coomber, E.R. Dufficy, et al. EROS/CYBC1 mutations: decreased NADPH oxidase function and chronic granulomatous disease. J. Allergy Clin. Immunol., 143 (2019), pp. 782-785. Available from http://www.jacionline.org/article/S0091674918314234/fulltext. [CrossRef]
- L.O. Randzavola, P.M. Mortimer, E. Garside, E.R. Dufficy, A.Schejtman, G. Roumelioti, et al. Title EROS-mediated control of NOX2 and P2X7 biosynthesis. (2021), 10.1101/2021.09.14.460103.
- G.A. Arnadottir, G.L. Norddahl, S. Gudmundsdottir, A.B.Agustsdottir, S. Sigurdsson, B.O. Jensson, et al. A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease. Nat. Commun. (2018), p. 9. [CrossRef]
- M. Chiriaco, A. De Matteis, C. Cifaldi, G. Di Matteo, B. Rivalta, C.Passarelli, et al. Characterization of AR-CGD female patient with a novel homozygous deletion in CYBC1 gene presenting with unusual clinical phenotype. Clin. Immunol., 251 (2023), Article 109316. [CrossRef]
- Heyworth P, Cross A, Curnutte J. Chronic granulomatous disease. Curr Opin Immunol 2003; 15: 578-84.
- Köker MY, Camcýoðlu Y, van Leeuwen K, Kýlýç SÞ, Barlan I, Yýlmaz M, et al. Clinical, functional, and genetic characterization of Chronic Granulomatous Disease in 89 turkish patients. J Allergy Clin Immunol 2013;132:1156-63.
- Belzer LT, Wright SM, Goodwin EJ, Singh MN, Carter BS. Psychosocial Considerations for the Child with Rare Disease: A Review with Recommendations and Calls to Action. Children (Basel). 2022 Jun 21;9(7):933. [CrossRef]
- Abd Hamid IJ, Slatter MA, McKendrick F, Pearce MS, Gennery AR. Long-Term Health Outcome and Quality of Life Post-HSCT for IL7Rα-, Artemis-, RAG1- and RAG2-Deficient Severe Combined Immunodeficiency: a Single Center Report. J Clin Immunol. 2018 Aug;38(6):727-732. [CrossRef]
- Andersen JB, Midttun K, Feragen KJB. Measuring quality of life of primary antibody deficiency patients using a disease-specific health-related quality of life questionnaire for common variable immunodeficiency (CVID_QoL). J Patient Rep Outcomes. 2019 Feb 26;3(1):15. [CrossRef]
- Gao S, Hu S, Duan H, Wang L, Kong X. Clinical characteristics and prenatal diagnosis for 22 families in Henan Province of China with X-linked agammaglobulinemia (XLA) related to Bruton’s tyrosine kinase (BTK) gene mutations. BMC Med Genet. 2020 Jun 17;21(1):131. [CrossRef]
- Pulvirenti F, Sangerardi M, Plebani A, Soresina A, Finocchi A, Pignata C et al. Health-Related Quality of Life and Emotional Difficulties in Chronic Granulomatous Disease: Data on Adult and Pediatric Patients from Italian Network for Primary Immunodeficiency (IPINet). J Clin Immunol. 2020 Feb;40(2):289-298. [CrossRef]
- Varni JW, Limbers CA, Burwinkle TM. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes. 2007 Jul 16;5:43. doi:10.1186/1477-7525-5-43.
- Cole T, McKendrick F, Titman P, Cant AJ, Pearce MS, Cale CM et al. Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. J Clin Immunol. 2013 Jan;33(1):8-13. [CrossRef]
- Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME et al. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015 Nov;35(8):696-726.
- Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022 Oct;42(7):1473-1507.
- Agudelo-Flórez P, Navarro S, Luttges P, López JA, Norambuena X, Navarrete S CL, et al. Identificación de mutaciones en el gen CYBB que llevan al fenotipo de la enfermedad granulomatosa crónica ligada al cromosoma X: reporte de una nueva mutación. Rev Med Chile 2006;134:965-72.
- Leiding JW, Holland SM. Chronic Granulomatous Disease. In: Pagon RA, Adam MP, Ardinger HH et al., editors. Gene Reviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.
- Holland SM. Chronic Granulomatous Disease. Clin Rev Allergy Immunol 2010; 38: 3-10.
- Van den Berg J, Van Koppen E, Ahlin A, Belohradsky B, Bernatowska E, Corbeel L. Chronic Granulomatous Disease: The European Experience. PLoS ONE. 2009;4:e5234. [CrossRef]
- Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol. 2007;148:79-84. [CrossRef]
- Roos D, de Boer M. Molecular diagnosis of chronic granulomatous disease. Clin Exp Immunol 2013; 175: 139-49. [CrossRef]
- Margolis DM, Melnick DA, Alling DW, Gallin JI: Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990;162:723-6.
- Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003;348:2416-22.
- Mouy R, Veber F, Blanche S, Donadieu J, Brauner R, Levron JC, et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr 1994;125:998-1003. [CrossRef]
- Petropoulou T, Liese J, Tintelnot K, Gahr M, Belohradsky BH. Long-term treatment of patients with itraconazole for the prevention of Aspergillus infections in patients with chronic granulomatous disease (CGD). Mycoses 1994;37:64-9.
- Gatlin JI, Malech HL, Weening RS, Curnutte JT, Quie PG, Jaffe HS, Ezekowitz RAB: A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991;324:509-16.
- Seger RA. Hematopoietic stemcell transplantation for chronic granulomatous disease. Immunol Allergy Clin North Am. 2010; 30: 195-208.
- Kang EM, Marciano BE, DeRavin S, Zarember KA, Holland SM, Malech HL. Chronic granulomatous disease: overview and hematopoietic stemcell transplantation versus conventional treatment. Acta Paediatrica 2013;102:1087-94.
- Åhlin A, Fugeläng J, de Boer M, Ringden O, Fasth A, Winiarski J. Chronic granulomatous disease – haematopoietic stemcell transplantation versus conventional treatment. Acta Pædiatrica 2013; 102: 1087-94.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).